PY1

**PY1** is a synthetic amino-pyrimidine–curcumin analog developed as a more chemically stable curcumin-derived antineoplastic research candidate. It is a direct curcumin homolog containing a pyrimidine-based central scaffold and showed in-vitro antiproliferative activity in androgen-sensitive LNCaP and androgen-insensitive PC3 prostate cancer cells, with reported GI50 values of approximately 24 µM in both models. PY1 was also evaluated in HT29 and HCT116 colorectal cancer cells. It remained stable in simulated physiological media and was predicted to be predominantly neutral at physiological pH. No clinical development, approved indication, dosage form, route of administration, or defined molecular target has been reported.